Big pharma dominates ranking of stocks with best five-year returns

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. ONON
6. AAPL
7. RTB
8. AZN
9. SPCX
10. TRMD

Go back to Big pharma dominates ranking of stocks with best five-year returns

Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform

May 5, 2016 3:25 PM EDT

Baird maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $505.00 (from $526.00), following the company's 1Q earnings report. EPS of $2.57 was reported in-line with expectations. Baird continues to believe that the copmant can deliver growth over the next few... More

Oppenheimer Cuts Price Target as Gilead Sciences (GILD) Reports 1Q Miss

May 4, 2016 8:43 AM EDT

Oppenheimer maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD), and cut the price target to $116.00 (from $120.00), following the company's 1Q earnings report. Gilead reported 1Q16 revenues of $7.79B, below consensus estimates of $8.06B. The top line miss was due to soft sales from... More

Leerink Modestly Positive on Biogen's (BIIB) Hemophilia Spin; Remains Cautious on Rest of Company

May 3, 2016 2:52 PM EDT

Leerink affirms Biogen (Nasdaq: BIIB) with a Market Perform rating and $319 price target following news that the company is going to spin-off its hemophilia unit.

Analyst Geoffrey Porges commented: In a somewhat surprising move, Biogen announced today that it will spin off its hemophilia business into an... More